Nasdaq · Healthcare
TSS, Inc. (TSSI)
As-reported financials and recent SEC filings for TSS, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$245.7M
Net income
$15.1M
Net margin
6.2%
Diluted EPS
$0.56
ROE
19.7%
P/E (TTM)
21.8×
Market cap
$317.8M
Debt / equity
0.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $245.7M | $148.1M | $54.4M | $30.6M | $27.4M |
| Gross profit | $32.4M | $22.4M | $11.0M | $9.0M | $6.4M |
| Operating income | $6.3M | $5.8M | $-221,000 | $914,000 | $-831,000 |
| Net income | $15.1M | $6.0M | $74,000 | $-73,000 | $-1.3M |
| Diluted EPS | $0.56 | $0.24 | $0.00 | $0.00 | $-0.07 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-04
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →SCHEDULE 13G2026-06-01
View on EDGAR →1442026-05-28
View on EDGAR →1442026-05-28
View on EDGAR →42026-05-08
View on EDGAR →8-K2026-05-07
View on EDGAR →Go deeper on TSSI
Search TSS, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.